Eye immune privilege? Nivolumab plus ipilimumab: successful treatment in a patient with cutaneous melanoma and ocular metastases
- PMID: 31022059
- DOI: 10.1097/CMR.0000000000000591
Eye immune privilege? Nivolumab plus ipilimumab: successful treatment in a patient with cutaneous melanoma and ocular metastases
Comment on
-
Immune privilege: failure of immunotherapy in controlling metastatic cutaneous melanoma to the eye.Melanoma Res. 2018 Aug;28(4):359-362. doi: 10.1097/CMR.0000000000000443. Melanoma Res. 2018. PMID: 29634634
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
